Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Saroglitazar - Zydus Cadila

Next Previous
Drug Profile

Saroglitazar - Zydus Cadila

Alternative Names: [14C] saroglitazar; [14C]-Saroglitazar; Bilypsa; Lipaglyn; Saroglitazar Magnesium; Saroglitazar Mg; ZY-H1

Latest Information Update: 27 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zydus-Cadila
  • Developer Zydus Cadila; Zydus Discovery DMCC
  • Class Antihyperglycaemics; Antihyperlipidaemics; Carboxylic acids; Hepatoprotectants; Propionic acids; Pyrroles; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary biliary cirrhosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dyslipidaemias; Hypertriglyceridaemia
  • Registered Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Phase III Lipodystrophy; Primary biliary cirrhosis
  • Phase II Liver disorders; Polycystic ovary syndrome

Most Recent Events

  • 13 May 2025 Zydus Discovery DMCC terminates a phase II trial in Non-alcoholic fatty liver disease in USA and Mexico due to sponsor decision (PO) (NCT03617263)
  • 07 May 2025 Zydus Therapeutics completes a phase IIb/III trial for Primary biliary cholangitis in USA, Argentina, Colombia, Iceland, Italy, Spain, Turkey, United Kingdom(NCT05133336)
  • 20 Feb 2025 Zydus Therapeutics plans a pharmacokinetics phase I trial (PO, Tablet) (NCT06825559)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top